Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Leases (2023 - 2025)

IGC Pharma (IGC) has disclosed Current Leases for 3 consecutive years, with $9000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 93.28% to $9000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $9000.0, a 93.28% decrease, with the full-year FY2025 number at $94000.0, down 24.19% from a year prior.
  • Current Leases was $9000.0 for Q3 2025 at IGC Pharma, down from $62000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $134000.0 in Q3 2024 to a low of $9000.0 in Q3 2025.
  • A 3-year average of $104111.1 and a median of $124000.0 in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: changed 0.0% in 2024, then plummeted 93.28% in 2025.
  • IGC Pharma's Current Leases stood at $124000.0 in 2023, then changed by 0.0% to $124000.0 in 2024, then plummeted by 92.74% to $9000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Current Leases are $9000.0 (Q3 2025), $62000.0 (Q2 2025), and $94000.0 (Q1 2025).